From 438c636ee67c3735859c6e7ddfc62081b3d1804a Mon Sep 17 00:00:00 2001
From: Teleo Agents <agents@livingip.xyz>
Date: Fri, 10 Apr 2026 01:10:53 +0000
Subject: [PATCH] reweave: connect 16 orphan claims via vector similarity

Threshold: 0.7, Haiku classification, 24 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
---
 ...-IHL-because-proportionality-requires-human-judgment.md | 2 ++
 ...ai-alignment-converge-on-explainability-requirements.md | 2 ++
 ...s-to-adverse-events-due-to-structural-reporting-gaps.md | 2 ++
 ...g-systematic-under-detection-of-ai-attributable-harm.md | 2 ++
 ...ailable-treatment-indicating-behavioral-sdoh-failure.md | 2 ++
 ...ed-1999-2023-becoming-leading-contributing-cvd-cause.md | 2 ++
 ...enrollment-stability-required-for-vbc-prevention-roi.md | 2 ++
 ...-food-assistance-reduction-history-186b-through-2034.md | 7 +++++++
 ...cological-availability-is-not-the-binding-constraint.md | 2 ++
 ...tide-shows-stronger-mace-reduction-than-select-trial.md | 7 +++++++
 ...g-active-harm-accumulation-not-after-safety-evidence.md | 2 ++
 ...of-weight-loss-with-inflammation-as-primary-mediator.md | 5 +++++
 ...ght-loss-suggesting-glp1r-specific-cardiac-mechanism.md | 2 ++
 ...cardiovascular-outcomes-despite-inferior-weight-loss.md | 3 +++
 ...hemic-declining-heart-failure-hypertension-worsening.md | 2 ++
 ...3-exceeding-baseline-despite-acute-care-improvements.md | 2 ++
 ... weakest financial position among funded competitors.md | 2 ++
 ...cceleration closing the reusability gap in 5-8 years.md | 4 ++++
 ...e-binding-constraint-for-commercial-station-programs.md | 4 ++++
 ...s a void that 4 companies are racing to fill by 2030.md | 6 ++++++
 ... structurally advantages nimble commercial providers.md | 4 ++++
 ...on-requires-independent-supply-and-demand-thresholds.md | 7 +++++++
 ...ears of continuous human presence in low Earth orbit.md | 7 +++++++
 entities/space-development/aetherflux.md                   | 4 ++++
 24 files changed, 84 insertions(+)

diff --git a/domains/ai-alignment/autonomous-weapons-violate-existing-IHL-because-proportionality-requires-human-judgment.md b/domains/ai-alignment/autonomous-weapons-violate-existing-IHL-because-proportionality-requires-human-judgment.md
index 115c9b94c..fc5ac3469 100644
--- a/domains/ai-alignment/autonomous-weapons-violate-existing-IHL-because-proportionality-requires-human-judgment.md
+++ b/domains/ai-alignment/autonomous-weapons-violate-existing-IHL-because-proportionality-requires-human-judgment.md
@@ -13,10 +13,12 @@ related_claims: ["[[AI alignment is a coordination problem not a technical probl
 supports:
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck'}
 - International humanitarian law and AI alignment research independently converged on the same technical limitation that autonomous systems cannot be adequately predicted understood or explained
+- Legal scholars and AI alignment researchers independently converged on the same core problem: AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck
 reweave_edges:
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-06'}
 - International humanitarian law and AI alignment research independently converged on the same technical limitation that autonomous systems cannot be adequately predicted understood or explained|supports|2026-04-08
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-09'}
+- Legal scholars and AI alignment researchers independently converged on the same core problem: AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-10
 ---
 
 # Autonomous weapons systems capable of militarily effective targeting decisions cannot satisfy IHL requirements of distinction, proportionality, and precaution, making sufficiently capable autonomous weapons potentially illegal under existing international law without requiring new treaty text
diff --git a/domains/ai-alignment/international-humanitarian-law-and-ai-alignment-converge-on-explainability-requirements.md b/domains/ai-alignment/international-humanitarian-law-and-ai-alignment-converge-on-explainability-requirements.md
index 31a6013b2..c267d3855 100644
--- a/domains/ai-alignment/international-humanitarian-law-and-ai-alignment-converge-on-explainability-requirements.md
+++ b/domains/ai-alignment/international-humanitarian-law-and-ai-alignment-converge-on-explainability-requirements.md
@@ -15,8 +15,10 @@ related:
 reweave_edges:
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|related|2026-04-08'}
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-09'}
+- Legal scholars and AI alignment researchers independently converged on the same core problem: AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-10
 supports:
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck'}
+- Legal scholars and AI alignment researchers independently converged on the same core problem: AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck
 ---
 
 # International humanitarian law and AI alignment research independently converged on the same technical limitation that autonomous systems cannot be adequately predicted understood or explained
diff --git a/domains/health/fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md b/domains/health/fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md
index 118c580ca..ce88aba1e 100644
--- a/domains/health/fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md
+++ b/domains/health/fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md
@@ -13,11 +13,13 @@ related_claims: ["[[healthcare AI regulation needs blank-sheet redesign because
 supports:
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm"}
 - FDA's MAUDE database systematically under-detects AI-attributable harm because it has no mechanism for identifying AI algorithm contributions to adverse events
+- The clinical AI safety gap is doubly structural: FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm
 reweave_edges:
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-07"}
 - FDA's MAUDE database systematically under-detects AI-attributable harm because it has no mechanism for identifying AI algorithm contributions to adverse events|supports|2026-04-07
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-08"}
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-09"}
+- The clinical AI safety gap is doubly structural: FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-10
 ---
 
 # FDA MAUDE reports lack the structural capacity to identify AI contributions to adverse events because 34.5 percent of AI-device reports contain insufficient information to determine causality
diff --git a/domains/health/fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md b/domains/health/fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md
index 4eeb45a4e..7a01f1f49 100644
--- a/domains/health/fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md
+++ b/domains/health/fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md
@@ -13,11 +13,13 @@ related_claims: ["[[human-in-the-loop clinical AI degrades to worse-than-AI-alon
 supports:
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm"}
 - FDA MAUDE reports lack the structural capacity to identify AI contributions to adverse events because 34.5 percent of AI-device reports contain insufficient information to determine causality
+- The clinical AI safety gap is doubly structural: FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm
 reweave_edges:
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-07"}
 - FDA MAUDE reports lack the structural capacity to identify AI contributions to adverse events because 34.5 percent of AI-device reports contain insufficient information to determine causality|supports|2026-04-07
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-08"}
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-09"}
+- The clinical AI safety gap is doubly structural: FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-10
 ---
 
 # FDA's MAUDE database systematically under-detects AI-attributable harm because it has no mechanism for identifying AI algorithm contributions to adverse events
diff --git a/domains/health/hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure.md b/domains/health/hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure.md
index c68338ef4..ccbfb5b83 100644
--- a/domains/health/hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure.md
+++ b/domains/health/hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure.md
@@ -18,10 +18,12 @@ reweave_edges:
 - us cvd mortality bifurcating ischemic declining heart failure hypertension worsening|supports|2026-04-04
 - Hypertension became the primary contributing cardiovascular cause of death in the US since 2022 marking a shift from acute ischemia to chronic metabolic disease as the dominant CVD mortality driver|supports|2026-04-07
 - Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden|supports|2026-04-07
+- US hypertension-related cardiovascular mortality nearly doubled from 2000 to 2019 while treatment and control rates stagnated for 15 years demonstrating structural access failure not drug unavailability|supports|2026-04-10
 supports:
 - us cvd mortality bifurcating ischemic declining heart failure hypertension worsening
 - Hypertension became the primary contributing cardiovascular cause of death in the US since 2022 marking a shift from acute ischemia to chronic metabolic disease as the dominant CVD mortality driver
 - Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden
+- US hypertension-related cardiovascular mortality nearly doubled from 2000 to 2019 while treatment and control rates stagnated for 15 years demonstrating structural access failure not drug unavailability
 ---
 
 # Hypertension-related cardiovascular mortality nearly doubled in the United States 2000–2023 despite the availability of effective affordable generic antihypertensives indicating that hypertension management failure is a behavioral and social determinants problem not a pharmacological availability problem
diff --git a/domains/health/hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md b/domains/health/hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md
index a4bb73c99..d602da65f 100644
--- a/domains/health/hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md
+++ b/domains/health/hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md
@@ -13,9 +13,11 @@ related_claims: ["[[Big Food companies engineer addictive products by hacking ev
 supports:
 - us cvd mortality bifurcating ischemic declining heart failure hypertension worsening
 - Hypertension became the primary contributing cardiovascular cause of death in the US since 2022 marking a shift from acute ischemia to chronic metabolic disease as the dominant CVD mortality driver
+- US hypertension-related cardiovascular mortality nearly doubled from 2000 to 2019 while treatment and control rates stagnated for 15 years demonstrating structural access failure not drug unavailability
 reweave_edges:
 - us cvd mortality bifurcating ischemic declining heart failure hypertension worsening|supports|2026-04-04
 - Hypertension became the primary contributing cardiovascular cause of death in the US since 2022 marking a shift from acute ischemia to chronic metabolic disease as the dominant CVD mortality driver|supports|2026-04-07
+- US hypertension-related cardiovascular mortality nearly doubled from 2000 to 2019 while treatment and control rates stagnated for 15 years demonstrating structural access failure not drug unavailability|supports|2026-04-10
 ---
 
 # Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden
diff --git a/domains/health/obbba-medicaid-work-requirements-destroy-enrollment-stability-required-for-vbc-prevention-roi.md b/domains/health/obbba-medicaid-work-requirements-destroy-enrollment-stability-required-for-vbc-prevention-roi.md
index db739704c..f8255fd36 100644
--- a/domains/health/obbba-medicaid-work-requirements-destroy-enrollment-stability-required-for-vbc-prevention-roi.md
+++ b/domains/health/obbba-medicaid-work-requirements-destroy-enrollment-stability-required-for-vbc-prevention-roi.md
@@ -12,11 +12,13 @@ sourcer: AMA / Georgetown CCF / Urban Institute
 related_claims: ["[[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]"]
 supports:
 - Medicaid work requirements cause coverage loss through procedural churn not employment screening because 5.3 million projected uninsured exceeds the population of able-bodied unemployed adults
+- Value-based care requires enrollment stability as structural precondition because prevention ROI depends on multi-year attribution and semi-annual redeterminations break the investment timeline
 challenges:
 - One Big Beautiful Bill Act (OBBBA)
 reweave_edges:
 - Medicaid work requirements cause coverage loss through procedural churn not employment screening because 5.3 million projected uninsured exceeds the population of able-bodied unemployed adults|supports|2026-04-09
 - One Big Beautiful Bill Act (OBBBA)|challenges|2026-04-09
+- Value-based care requires enrollment stability as structural precondition because prevention ROI depends on multi-year attribution and semi-annual redeterminations break the investment timeline|supports|2026-04-10
 ---
 
 # OBBBA Medicaid work requirements destroy the enrollment stability that value-based care requires for prevention ROI by forcing all 50 states to implement 80-hour monthly work thresholds by December 2026
diff --git a/domains/health/obbba-snap-cuts-largest-food-assistance-reduction-history-186b-through-2034.md b/domains/health/obbba-snap-cuts-largest-food-assistance-reduction-history-186b-through-2034.md
index 0a09b3a56..51a849614 100644
--- a/domains/health/obbba-snap-cuts-largest-food-assistance-reduction-history-186b-through-2034.md
+++ b/domains/health/obbba-snap-cuts-largest-food-assistance-reduction-history-186b-through-2034.md
@@ -10,6 +10,13 @@ agent: vida
 scope: structural
 sourcer: FRAC / Penn LDI / Urban Institute / Pew Charitable Trusts
 related_claims: ["[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]", "[[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"]
+supports:
+- SNAP benefit loss causes measurable mortality increases in under-65 populations through food insecurity pathways with peer-reviewed rate estimates of 2.9 percent excess deaths over 14 years
+reweave_edges:
+- SNAP benefit loss causes measurable mortality increases in under-65 populations through food insecurity pathways with peer-reviewed rate estimates of 2.9 percent excess deaths over 14 years|supports|2026-04-10
+- OBBBA SNAP cost-shifting to states creates a fiscal cascade where compliance with federal work requirements imposes $15 billion annual state costs, forcing states to cut additional health benefits to absorb the new burden|related|2026-04-10
+related:
+- OBBBA SNAP cost-shifting to states creates a fiscal cascade where compliance with federal work requirements imposes $15 billion annual state costs, forcing states to cut additional health benefits to absorb the new burden
 ---
 
 # OBBBA SNAP cuts represent the largest food assistance reduction in US history at $186 billion through 2034, removing continuous nutritional support from 2.4 million people despite evidence that SNAP participation reduces healthcare costs by 25 percent
diff --git a/domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md b/domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md
index edd9dcf46..83a05b80c 100644
--- a/domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md
+++ b/domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md
@@ -13,10 +13,12 @@ attribution:
       context: "JACC longitudinal study 1999-2023, NHANES nationally representative data"
 supports:
 - hypertension related cvd mortality doubled 2000 2023 despite available treatment indicating behavioral sdoh failure
+- US hypertension-related cardiovascular mortality nearly doubled from 2000 to 2019 while treatment and control rates stagnated for 15 years demonstrating structural access failure not drug unavailability
 reweave_edges:
 - hypertension related cvd mortality doubled 2000 2023 despite available treatment indicating behavioral sdoh failure|supports|2026-03-31
 - food as medicine interventions produce clinically significant improvements during active delivery but benefits fully revert when structural food environment support is removed|related|2026-04-03
 - generic digital health deployment reproduces existing disparities by disproportionately benefiting higher income users despite nominal technology access equity|related|2026-04-03
+- US hypertension-related cardiovascular mortality nearly doubled from 2000 to 2019 while treatment and control rates stagnated for 15 years demonstrating structural access failure not drug unavailability|supports|2026-04-10
 related:
 - food as medicine interventions produce clinically significant improvements during active delivery but benefits fully revert when structural food environment support is removed
 - generic digital health deployment reproduces existing disparities by disproportionately benefiting higher income users despite nominal technology access equity
diff --git a/domains/health/real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial.md b/domains/health/real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial.md
index 575fc2e2b..2c5b20b7c 100644
--- a/domains/health/real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial.md
+++ b/domains/health/real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial.md
@@ -10,6 +10,13 @@ agent: vida
 scope: correlational
 sourcer: Smolderen et al.
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+related:
+- Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction
+reweave_edges:
+- Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction|related|2026-04-10
+- Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction|supports|2026-04-10
+supports:
+- Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction
 ---
 
 # Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias
diff --git a/domains/health/regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md b/domains/health/regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md
index 8d8df516c..10bcdb162 100644
--- a/domains/health/regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md
+++ b/domains/health/regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md
@@ -16,6 +16,7 @@ supports:
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm"}
 - Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes
 - Regulatory vacuum emerges when deregulation outpaces safety evidence accumulation creating institutional epistemic divergence between regulators and health authorities
+- The clinical AI safety gap is doubly structural: FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm
 reweave_edges:
 - Clinical AI chatbot misuse is a documented ongoing harm source not a theoretical risk as evidenced by ECRI ranking it the number one health technology hazard for two consecutive years|supports|2026-04-03
 - FDA's 2026 CDS guidance expands enforcement discretion to cover AI tools providing single clinically appropriate recommendations while leaving clinical appropriateness undefined and requiring no bias evaluation or post-market surveillance|supports|2026-04-03
@@ -25,6 +26,7 @@ reweave_edges:
 - All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026|related|2026-04-07
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-08"}
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-09"}
+- The clinical AI safety gap is doubly structural: FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-10
 related:
 - All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026
 ---
diff --git a/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md b/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md
index e48cfbc5d..8807d5ab4 100644
--- a/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md
+++ b/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md
@@ -15,6 +15,11 @@ related:
 - Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias
 reweave_edges:
 - Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias|related|2026-04-09
+- Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction|supports|2026-04-10
+- Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction|supports|2026-04-10
+supports:
+- Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction
+- Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction
 ---
 
 # Semaglutide's cardiovascular benefit is approximately 67-69% independent of weight or adiposity change, with anti-inflammatory pathways (hsCRP) accounting for more of the benefit than weight loss
diff --git a/domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism.md b/domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism.md
index 6a7b0760f..26bb86b5f 100644
--- a/domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism.md
+++ b/domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism.md
@@ -12,8 +12,10 @@ sourcer: STEER investigators / Nature Medicine
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
 supports:
 - Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias
+- Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction
 reweave_edges:
 - Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias|supports|2026-04-09
+- Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction|supports|2026-04-10
 ---
 
 # Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction
diff --git a/domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss.md b/domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss.md
index 80d0d1d28..02eb3c239 100644
--- a/domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss.md
+++ b/domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss.md
@@ -14,6 +14,9 @@ related:
 - Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias
 reweave_edges:
 - Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias|related|2026-04-09
+- Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction|supports|2026-04-10
+supports:
+- Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction
 ---
 
 # Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction
diff --git a/domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md b/domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md
index 8650ddfec..a7d4c06e0 100644
--- a/domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md
+++ b/domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md
@@ -14,10 +14,12 @@ supports:
 - Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden
 - Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation
 - US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden
+- Long-term US cardiovascular mortality gains are slowing or reversing across major conditions as of 2026 after decades of continuous improvement
 reweave_edges:
 - Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden|supports|2026-04-07
 - Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation|supports|2026-04-07
 - US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden|supports|2026-04-07
+- Long-term US cardiovascular mortality gains are slowing or reversing across major conditions as of 2026 after decades of continuous improvement|supports|2026-04-10
 ---
 
 # US CVD mortality is bifurcating with ischemic heart disease declining while heart failure and hypertensive disease reach all-time highs revealing that aggregate improvement masks structural deterioration in cardiometabolic health
diff --git a/domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md b/domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md
index 38789ce08..20d7d290c 100644
--- a/domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md
+++ b/domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md
@@ -12,8 +12,10 @@ sourcer: Yan et al. / JACC
 related_claims: ["[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations]]"]
 supports:
 - us cvd mortality bifurcating ischemic declining heart failure hypertension worsening
+- Long-term US cardiovascular mortality gains are slowing or reversing across major conditions as of 2026 after decades of continuous improvement
 reweave_edges:
 - us cvd mortality bifurcating ischemic declining heart failure hypertension worsening|supports|2026-04-04
+- Long-term US cardiovascular mortality gains are slowing or reversing across major conditions as of 2026 after decades of continuous improvement|supports|2026-04-10
 ---
 
 # US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden
diff --git a/domains/space-development/Axiom Space has the strongest operational position for commercial orbital habitation but the weakest financial position among funded competitors.md b/domains/space-development/Axiom Space has the strongest operational position for commercial orbital habitation but the weakest financial position among funded competitors.md
index 3b9f1a783..5d11015f8 100644
--- a/domains/space-development/Axiom Space has the strongest operational position for commercial orbital habitation but the weakest financial position among funded competitors.md	
+++ b/domains/space-development/Axiom Space has the strongest operational position for commercial orbital habitation but the weakest financial position among funded competitors.md	
@@ -10,8 +10,10 @@ depends_on:
 - the commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit
 related:
 - Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s
+- Commercial station capital concentrates in the strongest contender rather than diversifying across the sector when government anchor customer commitments are uncertain
 reweave_edges:
 - Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s|related|2026-04-04
+- Commercial station capital concentrates in the strongest contender rather than diversifying across the sector when government anchor customer commitments are uncertain|related|2026-04-10
 ---
 
 # Axiom Space has the strongest operational position for commercial orbital habitation but the weakest financial position among funded competitors
diff --git a/domains/space-development/China is the only credible peer competitor in space with comprehensive capabilities and state-directed acceleration closing the reusability gap in 5-8 years.md b/domains/space-development/China is the only credible peer competitor in space with comprehensive capabilities and state-directed acceleration closing the reusability gap in 5-8 years.md
index c32867278..2f51a7c11 100644
--- a/domains/space-development/China is the only credible peer competitor in space with comprehensive capabilities and state-directed acceleration closing the reusability gap in 5-8 years.md	
+++ b/domains/space-development/China is the only credible peer competitor in space with comprehensive capabilities and state-directed acceleration closing the reusability gap in 5-8 years.md	
@@ -6,6 +6,10 @@ confidence: likely
 source: "Astra, web research compilation February 2026"
 created: 2026-03-20
 challenged_by: ["China's reusability timeline may be optimistic given that Long March 12A first-stage recovery failed in December 2025"]
+related:
+- Chinese commercial launch vehicles have failed on debut at higher rates than Chinese state launch, creating a meaningful gap between China's strategic space ambitions and commercial launch capability
+reweave_edges:
+- Chinese commercial launch vehicles have failed on debut at higher rates than Chinese state launch, creating a meaningful gap between China's strategic space ambitions and commercial launch capability|related|2026-04-10
 ---
 
 # China is the only credible peer competitor in space with comprehensive capabilities and state-directed acceleration closing the reusability gap in 5-8 years
diff --git a/domains/space-development/anchor-customer-uncertainty-is-now-the-binding-constraint-for-commercial-station-programs.md b/domains/space-development/anchor-customer-uncertainty-is-now-the-binding-constraint-for-commercial-station-programs.md
index 369f529b0..75ae17f09 100644
--- a/domains/space-development/anchor-customer-uncertainty-is-now-the-binding-constraint-for-commercial-station-programs.md
+++ b/domains/space-development/anchor-customer-uncertainty-is-now-the-binding-constraint-for-commercial-station-programs.md
@@ -10,6 +10,10 @@ agent: astra
 scope: causal
 sourcer: SpaceNews
 related_claims: ["[[space governance gaps are widening not narrowing because technology advances exponentially while institutional design advances linearly]]", "[[governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers]]", "[[commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030]]"]
+supports:
+- Commercial station capital concentrates in the strongest contender rather than diversifying across the sector when government anchor customer commitments are uncertain
+reweave_edges:
+- Commercial station capital concentrates in the strongest contender rather than diversifying across the sector when government anchor customer commitments are uncertain|supports|2026-04-10
 ---
 
 # Anchor customer uncertainty is now the binding constraint for commercial station programs not technical capability or launch costs
diff --git a/domains/space-development/commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030.md b/domains/space-development/commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030.md
index 16054729c..4077a1ab0 100644
--- a/domains/space-development/commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030.md	
+++ b/domains/space-development/commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030.md	
@@ -9,9 +9,15 @@ challenged_by:
 - Timeline slippage threatens a gap in continuous human orbital presence (unbroken since November 2000). Axiom's September 2024 cash crisis and down round shows how fragile commercial station timelines are. If none of the four achieve operational capability before ISS deorbits in 2031, the US could face its first period without permanent crewed LEO presence in 25 years.
 supports:
 - Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s
+- Commercial space station market has stratified into three tiers by development phase with manufacturing-ready programs holding structural advantage over design-phase competitors
+- Commercial station capital concentrates in the strongest contender rather than diversifying across the sector when government anchor customer commitments are uncertain
+- No commercial space station has announced a firm launch date as of March 2026, despite ISS 2030 retirement representing a hard operational deadline
 reweave_edges:
 - Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s|supports|2026-04-04
 - Anchor customer uncertainty is now the binding constraint for commercial station programs not technical capability or launch costs|related|2026-04-07
+- Commercial space station market has stratified into three tiers by development phase with manufacturing-ready programs holding structural advantage over design-phase competitors|supports|2026-04-10
+- Commercial station capital concentrates in the strongest contender rather than diversifying across the sector when government anchor customer commitments are uncertain|supports|2026-04-10
+- No commercial space station has announced a firm launch date as of March 2026, despite ISS 2030 retirement representing a hard operational deadline|supports|2026-04-10
 related:
 - Anchor customer uncertainty is now the binding constraint for commercial station programs not technical capability or launch costs
 ---
diff --git a/domains/space-development/governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers.md b/domains/space-development/governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers.md
index 5ecf60aa6..815633309 100644
--- a/domains/space-development/governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers.md	
+++ b/domains/space-development/governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers.md	
@@ -6,6 +6,10 @@ confidence: likely
 source: "Astra synthesis from NASA COTS/CRS program history, Rocket Lab SDA contract, Space Force FY2026 budget, ISS commercial successor contracts"
 created: 2026-03-08
 challenged_by: "The transition is uneven — national security missions still require bespoke classified systems that commercial providers cannot serve off-the-shelf. Cost-plus contracting persists in programs where requirements are genuinely uncertain (e.g., SLS, deep-space habitats). The 'buyer not builder' framing may overstate how much has actually changed outside LEO launch services."
+related:
+- Congressional ISS extension proposals reveal that the US government treats low-Earth orbit human presence as a strategic asset requiring government-subsidized continuity, not a pure commercial market
+reweave_edges:
+- Congressional ISS extension proposals reveal that the US government treats low-Earth orbit human presence as a strategic asset requiring government-subsidized continuity, not a pure commercial market|related|2026-04-10
 ---
 
 # governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers
diff --git a/domains/space-development/space-sector-commercialization-requires-independent-supply-and-demand-thresholds.md b/domains/space-development/space-sector-commercialization-requires-independent-supply-and-demand-thresholds.md
index f5ca43ab6..0b2b07fd7 100644
--- a/domains/space-development/space-sector-commercialization-requires-independent-supply-and-demand-thresholds.md
+++ b/domains/space-development/space-sector-commercialization-requires-independent-supply-and-demand-thresholds.md
@@ -10,6 +10,13 @@ agent: astra
 scope: structural
 sourcer: Astra
 related_claims: ["launch-cost-reduction-is-the-keystone-variable-that-unlocks-every-downstream-space-industry-at-specific-price-thresholds.md", "governments-are-transitioning-from-space-system-builders-to-space-service-buyers-which-structurally-advantages-nimble-commercial-providers.md"]
+related:
+- Commercial space station market has stratified into three tiers by development phase with manufacturing-ready programs holding structural advantage over design-phase competitors
+reweave_edges:
+- Commercial space station market has stratified into three tiers by development phase with manufacturing-ready programs holding structural advantage over design-phase competitors|related|2026-04-10
+- The demand threshold in space is defined by revenue model independence from government anchor demand, not by revenue magnitude|supports|2026-04-10
+supports:
+- The demand threshold in space is defined by revenue model independence from government anchor demand, not by revenue magnitude
 ---
 
 # Space sector commercialization requires two independent thresholds: a supply-side launch cost gate and a demand-side market formation gate
diff --git a/domains/space-development/the commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit.md b/domains/space-development/the commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit.md
index 3dbeb0474..e23392fc3 100644
--- a/domains/space-development/the commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit.md	
+++ b/domains/space-development/the commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit.md	
@@ -11,6 +11,13 @@ related:
 - Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s
 reweave_edges:
 - Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s|related|2026-04-04
+- Commercial space station market has stratified into three tiers by development phase with manufacturing-ready programs holding structural advantage over design-phase competitors|supports|2026-04-10
+- No commercial space station has announced a firm launch date as of March 2026, despite ISS 2030 retirement representing a hard operational deadline|supports|2026-04-10
+- Congressional ISS extension proposals reveal that the US government treats low-Earth orbit human presence as a strategic asset requiring government-subsidized continuity, not a pure commercial market|supports|2026-04-10
+supports:
+- Commercial space station market has stratified into three tiers by development phase with manufacturing-ready programs holding structural advantage over design-phase competitors
+- No commercial space station has announced a firm launch date as of March 2026, despite ISS 2030 retirement representing a hard operational deadline
+- Congressional ISS extension proposals reveal that the US government treats low-Earth orbit human presence as a strategic asset requiring government-subsidized continuity, not a pure commercial market
 ---
 
 # The commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit
diff --git a/entities/space-development/aetherflux.md b/entities/space-development/aetherflux.md
index 9c0dfbde3..d3b558b3b 100644
--- a/entities/space-development/aetherflux.md
+++ b/entities/space-development/aetherflux.md
@@ -9,6 +9,10 @@ status: active
 industry: [space-based solar power, orbital data centers, space infrastructure]
 website: 
 domain: space-development
+supports:
+- Breakthrough Energy Ventures' investment in Aetherflux's orbital solar infrastructure signals that space-based solar power has achieved credibility as a climate technology investment category at institutional investor level
+reweave_edges:
+- Breakthrough Energy Ventures' investment in Aetherflux's orbital solar infrastructure signals that space-based solar power has achieved credibility as a climate technology investment category at institutional investor level|supports|2026-04-10
 ---
 
 # Aetherflux